Stevanato Group (NYSE:STVN) Releases Earnings Results, Misses Expectations By $0.01 EPS

Stevanato Group (NYSE:STVN) released its earnings results on Tuesday. The company reported €0.16 EPS for the quarter, missing the consensus estimate of €0.17 by (€0.01), FiscalAI reports. The business had revenue of €326.06 million for the quarter. Stevanato Group had a net margin of 10.99% and a return on equity of 10.43%.

Here are the key takeaways from Stevanato Group’s conference call:

• Third-quarter results were solid: revenue rose 8% organically to €326.1 million, adjusted EBITDA increased 14% to €88.8 million, and the adjusted EBITDA margin expanded 150 basis points to 27.2%.
• Management reiterated full-year 2026 guidance, including revenue of €1.26–€1.28 billion, adjusted EBITDA of €335–€345.2 million, and adjusted diluted EPS of €0.60–€0.62; stronger BDS growth is expected to offset a lower engineering outlook.
• The company expects a temporary moderation in 2027 growth because one GLP-1 customer is reducing Nexa syringe volumes; management now expects low-single-digit growth rather than its longer-term high-single-digit to low-double-digit target, although it says most of the shortfall has been backfilled.
• Non-GLP biologics revenue grew more than 30% in the quarter and 13% year to date, while demand remains strong for Alba syringes, EZ-fill cartridges and vials, and delivery devices; management expects broader biologics and biosimilars demand to support a return to normalized growth beyond 2027.
• Engineering revenue fell 12% as customer orders were delayed, and management acknowledged that order conversion remains below target; the company is also evaluating the segment’s strategic role because its visual inspection and assembly activities are dilutive to corporate margins.

Stevanato Group Stock Performance

STVN stock traded down €1.31 during mid-day trading on Wednesday, hitting €12.79. 1,627,321 shares of the company were exchanged, compared to its average volume of 519,795. The company has a current ratio of 1.61, a quick ratio of 1.08 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $3.87 billion, a PE ratio of 22.93, a price-to-earnings-growth ratio of 1.62 and a beta of 0.80. Stevanato Group has a 1-year low of €12.82 and a 1-year high of €27.00. The business has a 50 day simple moving average of €20.35 and a 200-day simple moving average of €18.11.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on STVN. Weiss Ratings raised shares of Stevanato Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, August 27th. UBS Group started coverage on Stevanato Group in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $23.00 price objective for the company. William Blair lowered Stevanato Group to a “market perform” rating in a report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Stevanato Group in a research note on Wednesday, October 7th. They set a “hold” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Stevanato Group currently has an average rating of “Moderate Buy”.

More Stevanato Group News

Here are the key news stories impacting Stevanato Group this week:

• Positive Sentiment: Third-quarter revenue rose 8% year over year to €326.1 million, and reports said the result exceeded revenue estimates. This indicates continued business growth, although it has been overshadowed by the outlook. Stevanato Group Q3 results
• Neutral Sentiment: Kehoe Law Firm and SueWallSt announced investor investigations following STVN’s decline, concerning whether company disclosures complied with securities laws. These are announcements of investigations, not findings of wrongdoing, and do not add new operating information. Kehoe Law Firm investigation notice SueWallSt investigation notice
• Negative Sentiment: Stevanato expects only low-single-digit growth in 2027, with lower GLP-1 syringe volumes from a single customer cited as a factor. That outlook raises concerns about growth beyond the strong third quarter and is the clearest reason for pressure on the shares. 2027 growth outlook

Insider Activity

In other Stevanato Group news, CFO Marco Dal Lago sold 4,209 shares of Stevanato Group stock in a transaction dated Friday, August 7th. The stock was sold at an average price of €20.09, for a total value of €84,558.81. Following the transaction, the chief financial officer owned 81,144 shares in the company, valued at €1,630,182.96. The trade was a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mauro Stocchi sold 13,649 shares of the stock in a transaction on Monday, September 28th. The shares were sold at an average price of €21.50, for a total value of €293,453.50. Following the completion of the sale, the insider owned 400,000 shares of the company’s stock, valued at €8,600,000. The trade was a 3.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 21,926 shares of company stock worth $459,738.

Institutional Investors Weigh In On Stevanato Group

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. State of Wyoming purchased a new stake in shares of Stevanato Group during the third quarter valued at $75,000. Schwartz Investment Counsel Inc. boosted its stake in shares of Stevanato Group by 15.0% in the third quarter. Schwartz Investment Counsel Inc. now owns 661,136 shares of the company’s stock worth $13,871,000 after acquiring an additional 86,385 shares during the period. PineStone Asset Management Inc. grew its holdings in Stevanato Group by 8.4% during the 3rd quarter. PineStone Asset Management Inc. now owns 41,335 shares of the company’s stock valued at $867,000 after buying an additional 3,200 shares in the last quarter. Fenimore Asset Management Inc bought a new position in Stevanato Group during the third quarter valued at approximately $12,212,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in shares of Stevanato Group during the 2nd quarter valued at about $59,000.

Stevanato Group Company Profile

Stevanato Group S.p.A. is an Italy-based provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and healthcare industries. Founded in 1949, the company has developed from a glass-packaging manufacturer into an integrated supplier serving customers throughout the global pharmaceutical supply chain.

The company manufactures primary packaging products, including glass vials, syringes, cartridges and ampoules, as well as components and systems used to contain and administer injectable medicines.